Nuvo Pharmaceuticals Inc.
Nuvo Pharmaceuticals Inc. Fundamental Analysis
Nuvo Pharmaceuticals Inc. (MRV.TO) shows weak financial fundamentals with a PE ratio of -19.29, profit margin of N/A, and ROE of N/A. The company generates N/A in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 0.0/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze MRV.TO's fundamental strength across five key dimensions:
Efficiency Score
WeakMRV.TO struggles to generate sufficient returns from assets.
Valuation Score
ModerateMRV.TO shows balanced valuation metrics.
Growth Score
WeakMRV.TO faces weak or negative growth trends.
Financial Health Score
WeakMRV.TO carries high financial risk with limited liquidity.
Profitability Score
WeakMRV.TO struggles to sustain strong margins.
Key Financial Metrics
Is MRV.TO Expensive or Cheap?
P/E Ratio
MRV.TO trades at -19.29 times earnings. This suggests potential undervaluation.
How Well Does MRV.TO Make Money?
No data available.
Following the Money - Real Cash Generation
No data available.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
N/A
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
N/A
vs 25 benchmark
P/B Ratio
Price to book value ratio
N/A
vs 25 benchmark
P/S Ratio
Price to sales ratio
N/A
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
N/A
vs 25 benchmark
Current Ratio
Current assets to current liabilities
N/A
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
N/A
vs 25 benchmark
ROA
Return on assets percentage
N/A
vs 25 benchmark
ROCE
Return on capital employed
N/A
vs 25 benchmark
How MRV.TO Stacks Against Its Sector Peers
| Metric | MRV.TO Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | N/A | 28.31 | N/A |
| ROE | N/A | 699.00% | N/A |
| Net Margin | N/A | -131318.00% (disorted) | N/A |
| Debt/Equity | N/A | 0.34 | N/A |
| Current Ratio | N/A | 2775.16 | N/A |
| ROA | N/A | -14513.00% (disorted) | N/A |
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Nuvo Pharmaceuticals Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Defensive, Growth, Innovation
EPS CAGR
N/A
Industry Style: Defensive, Growth, Innovation
FCF CAGR
N/A
Industry Style: Defensive, Growth, Innovation